Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.

被引：0
|
作者：
Warner, Allison Betof [1 ]
Shoushtari, Alexander Noor [1 ]
Houghton, Sean [1 ]
Panageas, Katherine [1 ]
Chapman, Paul B. [1 ]
Wolchok, Jedd D. [1 ]
Postow, Michael A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9552
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Characterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone
    Robert, C.
    Larkin, J.
    Ascierto, P. A.
    Long, G. V.
    Hassel, J. C.
    Schadendorf, D.
    Hodi, F. S.
    Lebbe, C.
    Grob, J-J.
    Grossmann, K.
    Wagstaff, J.
    Chesney, J.
    Hogg, D.
    Bechter, O.
    Marquez-Rodas, I.
    Pavlick, A. C.
    Walker, D.
    Bhore, R.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL)
    Sznol, M.
    Ferrucci, P. F.
    Hogg, D.
    Atkins, M.
    Wolter, P.
    Guidoboni, M.
    Lebbe, C.
    Kirkwood, J.
    Schachter, J.
    Daniels, G.
    Hassel, J.
    Cebon, J.
    Gerritsen, W.
    Atkinson, V.
    Thomas, L.
    McCaffrey, J.
    Power, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Clinical characteristics of responders to nivolumab plus ipilimumab (Nivo/Ipi) in metastatic uveal melanoma.
    Shephard, Michael Paul
    Glover, Maura
    Balmes, Gener
    Cain, Suzanne
    Vardeleon, Anna
    Mouton, Rosalind
    Posada, Liberty
    Simien, Rinata
    Hwu, Patrick
    Davies, Michael
    Yee, Cassian
    Wong, Michael
    Tawbi, Hussein
    Woodman, Scott
    Amaria, Rodabe
    Diab, Adi
    Glitza, Isabella
    Hwu, Wen-Jen
    Patel, Sapna
    CANCER RESEARCH, 2020, 80 (19) : 38 - 38
  • [4] ASSESSMENT OF THE IMMUNOGENICITY OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN COMBINATION AND POTENTIAL IMPACT ON SAFETY AND EFFICACY IN PATIENTS WITH ADVANCED MELANOMA.
    Statkevich, P.
    Passey, C.
    Park, J.
    Saeger, S.
    Bello, A.
    Roy, A.
    Agrawal, S.
    Gupta, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S9 - S9
  • [5] Characterisation of Complete Responses (CRS) in Patients With Advanced Melanoma (MEL) who Received the Combination of Nivolumab (NIVO) and Ipilimumab (IPI), NIVO, or IPI Alone
    Robert, Caroline
    Larkin, James
    Ascierto, Paolo A.
    Long, Georgina V.
    Hassel, Jessica C.
    Schadendorf, Dirk
    Hodi, F. Stephen
    Lebbe, Celeste
    Grob, Jean-Jacques
    Grossmann, Kenneth
    Wagstaff, John
    Chesney, Jason
    Hogg, David
    Bechter, Oliver
    Marquez-Rodas, Ivan
    Pavlick, Anna C.
    DanaWalker
    Bhore, Rafia
    Postow, Michael A.
    Wolchok, Jedd D.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 136 - 137
  • [6] SAFETY PROFILE OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) COMBINATION THERAPY IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Sznol, Mario
    Ferrucci, Pier
    Hogg, David
    Atkins, Michael
    Wolter, Pascal
    Guidoboni, Massimo
    Lebbe, Celeste
    Kirkwood, John
    Schachter, Jacob
    Daniels, Gregory
    Hassel, Jessica
    Cebon, Jonathan
    Gerritsen, Winald
    Atkinson, Victoria
    Thomas, Luc
    Mccaffrey, John
    Power, Derek
    Jiang, Joel
    Hodi, Stephen
    Wolchok, Jedd
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 118 - 118
  • [7] The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with uveal melanoma (UM).
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Diab, Adi
    Amaria, Rodabe Navroze
    Davies, Michael A.
    Hwu, Patrick
    Tawbi, Hussein Abdul-Hassan
    Hwu, Wen-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO plus IPI) or NIVO alone
    Robert, C.
    Long, G. V.
    Larkin, J.
    Wolchok, J. D.
    Hassel, J. C.
    Schadendorf, D.
    Hodi, F. S.
    Lebbe, C.
    Grob, J-J.
    Grossmann, K.
    Wagstaff, J.
    Chesney, J.
    Butler, M. O.
    Bechter, O.
    Marquez-Rodas, I.
    Pavlick, A. C.
    Re, S.
    van Dijck, W.
    Postow, M. A.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S734 - S735
  • [9] ASSESSMENT OF THE IMMUNOGENICITY OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN COMBINATION AND POTENTIAL IMPACT ON SAFETY AND EFFICACY IN PATIENTS WITH ADVANCED MELANOMA
    Statkevich, P.
    Passey, C.
    Park, J.
    Saeger, S.
    Bello, A.
    Roy, A.
    Agrawal, S.
    Gupta, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S64 - S64
  • [10] Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec plus Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.
    Almutairi, Abdulaali
    Alsaid, Nimer
    Oh, Mok
    Babiker, Hani M.
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345